Remove Development Remove Drug Trials Remove Marketing
article thumbnail

Small Pharma stock market launch funds DMT-based depression drug trial

pharmaphorum

UK-based Small Pharma has launched on the Toronto’s TSX Venture Exchange, raising 58 million Canadian dollars (around £34m) to develop medicines based on N,N-dimethyltriptylene (DMT) to treat depression. The post Small Pharma stock market launch funds DMT-based depression drug trial appeared first on.

article thumbnail

GSK suffers another R&D setback, axing ulcerative colitis drug trial

pharmaphorum

GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with ulcerative colitis, following a major disappointment with a key lung cancer drug last week. The post GSK suffers another R&D setback, axing ulcerative colitis drug trial appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leading clinical packaging companies in contract marketing

Pharmaceutical Technology

Unlike commercial pharmaceutical packaging, the primary consideration in clinical trial packaging is protecting the product quality and reliability for research. Finding the best clinical trial packaging services providers.

Packaging 100
article thumbnail

How using AI in clinical trials accelerates drug development

Pharmaceutical Technology

But before pharmaceutical companies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Pharma R&D teams are solving this problem by leveraging the power of artificial intelligence (AI) in clinical trials to save time and money.

article thumbnail

LSD biotech MindMed buys digital trial firm HealthMode

pharmaphorum

million, which uses artificial intelligence (AI) technology to speed up drug development. With the acquisition MindMed gains access to HealthMode’s intellectual property, platforms for clinical drug trials, and its entire 24-strong digital medicine team.

Trials 134
article thumbnail

Zealand Pharma Stock Surge on Liver Disease Drug Trial Data

Roots Analysis

Shares of Zealand Pharma experienced a significant surge, jumping 16% as the market opened on Monday, following the release of groundbreaking phase II trial results for an experimental obesity treatment being developed in collaboration with Boehringer Ingelheim.

article thumbnail

How does HTA for orphan drugs differ across Europe?

pharmaphorum

Several factors make it difficult for HTA bodies often to assess orphan drugs, including a lack of robust trial data due to difficulties in finding patients, the absence of randomised controlled trials, the use of surrogate endpoints, and the lack of active drug comparators. Source: CRA Analysis.

Drugs 122